| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Matthew Gryga Irrevocable Trust | 7.7% | $295,684 | 739,211 | Jeffrey Matthew Gryga Irrevocable Trust | 24 Oct 2025 | |||
| Empery Asset Management, LP | 5% | -50% | $201,636 | -$179,638 | 504,091 | -47% | Empery Asset Management, LP | 30 Sep 2025 |
| CVI Investments, Inc. | 4.9% | $166,595 | 146,136 | CVI Investments, Inc. | 31 Dec 2024 |
As of 30 Sep 2025, 18 institutional investors reported holding 437,052 shares of Theriva Biologics, Inc. - Common stock (TOVX). This represents 4.6% of the company’s total 9,600,143 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 5 | $1 | +$1 | $0.20 | 1 |
| 2025 Q3 | 437,052 | $177,030 | +$57,424 | $0.41 | 18 |
| 2025 Q2 | 291,012 | $126,275 | +$38,329 | $0.43 | 15 |
| 2025 Q1 | 190,680 | $209,750 | +$165,876 | $1.10 | 9 |
| 2024 Q4 | 34,470 | $60,008 | -$627,702 | $1.75 | 9 |
| 2024 Q3 | 491,424 | $677,871 | +$471,524 | $1.38 | 16 |